1-Year Comparison of Clinical and Endoscopic Outcomes of Tofacitinib vs Vedolizumab for Ulcerative Colitis After Anti-Tumor Necrosis Factor Failure: A Real-World Cohort Study in the United States

被引：0
|
作者：
Dalal, Rahul S. [1 ]
Sharma, Puza P. [2 ]
Bains, Kanwal [3 ]
Pruce, Jordan C. [1 ]
Allegretti, Jessica R. [1 ,4 ]
机构：
[1] Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Div Gastroenterol Hepatol & Endoscopy, Boston, MA USA
[2] Pfizer Inc, New York, NY USA
[3] Harvard Med Sch, Brigham & Womens Hosp, Dept Nutr, Boston, MA USA
[4] 50 Boylston St,Suite 201, Chestnut Hill, MA 02467 USA
来源：
INFLAMMATORY BOWEL DISEASES | 2023年 / 30卷 / 08期
关键词：
inflammatory bowel disease; small molecule; biologic; MAINTENANCE THERAPY; INDUCTION;
D O I：
10.1093/ibd/izad165
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
In this retrospective cohort study, tofacitinib was associated with higher adjusted odds of steroid-free clinical remission at 52 weeks and endoscopic remission within 52 weeks compared with vedolizumab. Adverse events were consistent with the known safety profiles of these agents.
引用
收藏
页码：1419 / 1422
页数：4
相关论文
共 40 条
  • [1] One-Year Comparison of Clinical and Endoscopic Outcomes of Tofacitinib Versus Vedolizumab for Ulcerative Colitis After Anti-Tumor Necrosis Factor Failure: A Real-World Cohort Study in the United States
    Dalal, R.
    Sharma, P.
    Bains, K.
    Pruce, J.
    Allegretti, J.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 677 - 678
  • [2] ONE-YEAR COMPARISON OF CLINICAL AND ENDOSCOPIC OUTCOMES OF TOFACITINIB VERSUS VEDOLIZUMAB FOR ULCERATIVE COLITIS AFTER ANTI-TUMOR NECROSIS FACTOR FAILURE: A REAL-WORLD COHORT STUDY IN THE UNITED STATES
    Dalal, Rahul S.
    Sharma, Puza P.
    Bains, Kanwal
    Pruce, Jordan C.
    Allegretti, Jessica R.
    GASTROENTEROLOGY, 2023, 164 (06) : S651 - S651
  • [3] Real-world clinical and endoscopic outcomes after one year tofacitinib treatment in ulcerative colitis
    Straatmijer, Tessa
    van Gennep, Sara
    Duijvestein, Marjolijn
    Ponsioen, Cyriel I. J.
    Gecse, Krisztina B.
    D'Haens, Geert R.
    Lowenberg, Mark
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2021, 33 (10) : 1288 - 1297
  • [4] One-Year Comparative Effectiveness of Ustekinumab vs Tofacitinib for Ulcerative Colitis After Anti-Tumor Necrosis Factor Failure
    Dalal, Rahul
    Sharma, Puza
    Bains, Kanwal
    Pruce, Jordan
    Allegretti, Jessica R.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S501 - S502
  • [5] REAL-WORLD TREATMENT PATTERNS AND OUTCOMES OF VEDOLIZUMAB VS. ANTI-TUMOR NECROSIS FACTOR IN BIOLOGIC-NAIVE ULCERATIVE COLITIS PATIENTS IN A NATIONWIDE HEALTHCARE PROVIDER DATABASE IN ISRAEL
    Weil, C.
    Chodick, G.
    Tsukinovsky, S.
    Ben Baruch, O.
    Barak, M.
    Sommer, A.
    VALUE IN HEALTH, 2020, 23 : S532 - S532
  • [6] Lesson from Real-World Experience: Optimal Treatment with Anti-Tumor Necrosis Factor for Ulcerative Colitis
    Chun, Jaeyoung
    GUT AND LIVER, 2021, 15 (06) : 793 - 794
  • [7] 1-Year Comparative Effectiveness of Tofacitinib vs Ustekinumab for Patients With Ulcerative Colitis and Prior Antitumor Necrosis Factor Failure
    Dalal, Rahul S.
    Sharma, Puza P.
    Bains, Kanwal
    Pruce, Jordan C.
    Allegretti, Jessica R.
    INFLAMMATORY BOWEL DISEASES, 2024, 30 (03) : 395 - 401
  • [8] REAL-WORLD MULTICENTER COMPARISON OF EFFECTIVENESS BETWEEN TOFACITINIB AND VEDOLIZUMAB IN PATIENTS WITH ULCERATIVE COLITIS AFTER FAILURE TO AT LEAST ONE ANTI-TNF AGENT
    Buisson, Anthony
    Nachury, Maria
    Fumery, Mathurin
    Guilmoteau, Thomas
    Leclerc, Eloise
    Altwegg, Romain
    Serrero, Melanie
    Mathieu, Nicolas
    Treton, Xavier
    Vuitton, Lucine
    Pereira, Bruno
    Amiot, Aurelien
    Bouguen, Guillaume
    GASTROENTEROLOGY, 2022, 162 (07) : S604 - S604
  • [9] Real-world multicenter comparison of effectiveness between tofacitinib and vedolizumab in patients with Ulcerative Colitis after failure to at least one anti-TNF agent
    Buisson, A.
    Nachury, M.
    Fumery, M.
    Guilmoteau, T.
    Leclerc, E.
    Altwegg, R.
    Serrero, M.
    Mathieu, N.
    Treton, X.
    Vuitton, L.
    Pereira, B.
    Amiot, A.
    Bouguen, G.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I120 - I120
  • [10] TOFACITINIB INDUCES CLINICAL AND ENDOSCOPIC REMISSION IN BIOLOGIC REFRACTORY ULCERATIVE COLITIS PATIENTS: A REAL-WORLD BELGIUM COHORT STUDY
    Cremer, Anneline
    Lobaton, Triana
    Vieujean, Sophie
    Bossuyt, Peter
    Rahier, Jean-Francois
    Baert, Filip J.
    Dewit, Olivier
    Macken, Elisabeth
    Somers, Michael
    Vijverman, Anne
    Van Hootegem, Philippe
    Mana, Fazia
    Willandt, Barbara
    Caenepeel, Philip
    Humblet, Evelien
    D'Heygere, Francois
    Verreth, Annelies
    El Nawar, Abdo
    Coenegrachts, Jean-Louis
    Dewit, Sophie
    De Coninck, Steven
    Schoofs, Nele
    Delen, Stefan
    Dutre, Joris
    Thienpont, Clara
    Vanden Branden, Stijn
    Staessen, Dirk
    Franchimont, Denis
    GASTROENTEROLOGY, 2020, 158 (06) : S1208 - S1208
1234